Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.40 |
| ▸ | AGER | Q15109 | 3/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565752 | 1.00 | LMNA (0.41) | LMNAOPRM1CCR5AGERMTNR1A | |
| SCHEMBL565751 | 0.89 | LMNA (0.48) | LMNAOPRM1CCR5AGERMTNR1A | |
| SCHEMBL566999 | 0.89 | LMNA (0.48) | LMNAOPRM1CCR5AGERMTNR1A | |
| SCHEMBL567000 | 0.89 | LMNA (0.48) | LMNAOPRM1CCR5AGERMTNR1A | |
| SCHEMBL567001 | 0.89 | LMNA (0.48) | LMNAOPRM1CCR5AGERMTNR1A | |
| SCHEMBL3370759 | 0.77 | AGER (0.55) | LMNAOPRM1AGERMTNR1ACHRM2 | |
| SCHEMBL383264 | 0.73 | CCR5 (0.47) | LMNACCR5 | |
| SCHEMBL2144199 | 0.73 | CCR5 (0.47) | LMNACCR5 | |
| SCHEMBL383265 | 0.73 | CCR5 (0.47) | LMNACCR5 | |
| SCHEMBL28453033 | 0.73 | CCR5 (0.46) | LMNACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035213-A1 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035213-A1 | Quinoline derivative | MC1R, MCHR1, MCHR2 | LMNA 4478/4885OPRM1 96/4885CCR5 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.